2026-04-19T19:21:36Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/74962026-04-04T03:12:27Zcom_2072_378070com_2072_378040col_2072_378092

Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B Ubals Cazorla, Maria Bosch Nicolau, Pau Sánchez Montalvá, Adrián Aparicio Español, Gloria Sulleiro Igual, Elena Silgado Gimenez, Aroa Soriano-Arandes, Antoni Espiau Guarner, Maria Ferrer Fábrega, Berta García-Patos Briones, Vicente Pou Ciruelo, Diana Treviño Maruri, Begoña Molina Romero, Israel Salvador Velez, Fernando M Institut Català de la Salut [Ubals M] Servei de Dermatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Doctoral Programme in Medicine and Translational Research: International Health Track, Facultat de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain. [Bosch-Nicolau P, Sánchez-Montalvá A, Salvador F, Molina I] Departament de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Aparicio-Español G, García-Patos V] Servei de Dermatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Facultat de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Sulleiro E, Silgado A] Servei de Microbiologia Clínica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Soriano-Arandes A, Espiau M] Servei de Pediatria, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Ferrer B] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Pou D, Treviño B] Unitat de Medicina Tropical i Salut Internacional, Drassanes- Vall d’Hebron Hospital Universitari, Barcelona, Spain. PROSICS Barcelona Vall d'Hebron Barcelona Hospital Campus Leishmaniosi - Tractament Medicaments antiinfecciosos - Ús terapèutic Avaluació de resultats (Assistència sanitària) DISEASES::Parasitic Diseases::Parasitic Diseases::Skin Diseases, Parasitic::Leishmaniasis::Leishmaniasis, Cutaneous Other subheadings::Other subheadings::Other subheadings::/drug therapy CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiparasitic Agents::Antiprotozoal Agents Other subheadings::Other subheadings::/therapeutic use ENFERMEDADES::enfermedades parasitarias::enfermedades parasitarias::enfermedades cutáneas parasitarias::leishmaniosis::leishmaniasis cutánea Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antiparasitarios::antiprotozoarios Otros calificadores::Otros calificadores::/uso terapéutico Leishmania; Anfotericina B liposomal; Terapia sistémica Leishmania; Liposomal amphotericin B; Systemic therapy Leishmania; Amfotericina B liposomal; Teràpia sistèmica Background: There is no consensus for the best treatment of complex cutaneous leishmaniasis (CL). We aimed to describe a cohort of CL, focusing on liposomal amphotericin B (L-AmB) treatment outcome. Methods: We performed a retrospective study in Vall d’Hebron University Hospital (Barcelona, Spain). All patients with parasitologically proven CL diagnosed from 2012 to 2018 were included. Results: The analysis included 41 patients with CL. The median age was 39 years (IQR 12- 66); 12 (29%) were children, and 29 (71%) were men. Regarding treatment, 24 (59%) received local treatment, whereas 17 (41%) had complex CL and were offered intravenous systemic treatment. Sixteen patients received L-AmB; eight (50%) had adverse events, and three (19%) discontinued treatment for safety reasons. All cases were considered cured within the first year post-treatment. Conclusions: L-AmB for complex CL showed no treatment failures, offering an alternative treatment option for patients with complex CL. Clinicians should pay close attention to the potential adverse events of L-AmB and adopt an active drug safety surveillance scheme to rapidly detect reversible side effects. This research received no external funding. 2022-05-06T13:27:23Z 2022-05-06T13:27:23Z 2021-10 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Ubals M, Bosch-Nicolau P, Sánchez-Montalvá A, Salvador F, Aparicio-Español G, Sulleiro E, et al. Treatment of Complex Cutaneous Leishmaniasis with Liposomal Amphotericin B. Pathogens. 2021 Oct;10(10):1253. 2076-0817 https://hdl.handle.net/11351/7496 10.3390/pathogens10101253 34684202 000711470100001 eng Pathogens;10(10) https://doi.org/10.3390/pathogens10101253 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess application/pdf application/pdf MDPI Scientia